Citaat:
Oorspronkelijk geplaatst door Deman
What we can now say is that finasteride not only significantly reduces a man’s risk of prostate cancer, it is safe to use based on very long-term follow-up in our study,” said Thompson. “In PCPT, we found no increased risk of prostate cancer death in men who took finasteride compared with men who did not. These results are transformational. Prostate cancer is the most common cancer diagnosed in American men, and we have found an inexpensive, effective drug that can prevent it. I’m pleased to report that we’ve answered the questions and closed the book.”
Thompson is chair of SWOG’s genitourinary cancer committee, overseeing development of all urologic cancer studies for the federally-funded cancer clinical trials group, and serves as president of CHRISTUS Santa Rosa Hospital - Medical Center in San Antonio, Texas and as emeritus professor at the University of Texas Health Science Center. Thompson led SWOG’s landmark PCPT. He and his team set out to determine whether finasteride, a drug used to treat symptoms of prostate enlargement as well as male pattern baldness, would prevent prostate cancer in men over the age of 55. At the time, scientists and doctors knew that prostate cancers were hormonally sensitive, and finasteride, the first 5-alpha-reductase inhibitor, which targets and blocks the action of androgens like testosterone, became available to test.
The PCPT randomized 18,882 men from 1993 to 1997 to finasteride or a placebo – making it one of the largest cancer prevention trials ever mounted. The trial intervention was stopped in 2003 when investigators found a significant, positive result: finasteride reduced prostate cancer risk by 25 percent. But the study also showed that finasteride produced a small increase in the number of high-grade prostate cancers – a negative finding that resulted in a “black box” warning posted by the U.S. Food and Drug Administration on prescription drug labels to flag potentially disabling or life-threatening side effects.
|
Een studie over prostaat kanker met niets over mogelijke bijwerkingen? Lol probeer beter vriend.
Over prostaat kanker en fina gesproken:
Fina maskeert ook prostaatkanker symptomen. Zeker belangrijk voor alle mannen om bewust te zijn van dit aangezien dit de meest voorkomende kanker is bij mannen:
Propecia has been proven to mask some of the symptoms and effects of prostate cancer, like prostate enlargement and elevated levels of a chemical called PSA which is produced by the prostate. This may interfere with early detection and diagnosis, meaning that for men taking Propecia prostate cancer may develop into a more advanced and aggressive stage before treatment is begun and therefore result in a worse prognosis. The FDA warns all physicains to be aware of the symptom-masking effects of Propecia and urges patients to discuss screening options with their doctors while taking Propecia.
The FDA has issued several warnings about Propecia and prostate cancer. Federal regulators have issued similar warnings for Proscar, Avodart, Jalyn, generic formulations of Propecia, and other drugs (called 5-ARIs) that are similar to Propecia.
The following Propecia prostate cancer FDA warnings apply to all drugs in this class:
• On June 9th, 2011, the FDA issued a Drug Safety Communication warning the public that Propecia may increase the risk of a more serious form of prostate cancer.
• The FDA prescribing information product label for Propecia was also updated to include the warning about high-grade prostate cancer. The information cautions that Propecia reduces PSA levels and urges doctors to take this into account when testing for prostate cancer.
http://paact.help/propecia-and-prostate-cancer/
Citaat:
Oorspronkelijk geplaatst door Deman
Before now, there has been no study of finasteride use exceeding 1 year in Japanese men with androgenetic alopecia (AGA) except the study subsequently conducted from the development phase. Since the launch of finasteride, no study in a larger population had been reported. Ethnic variation of the onset age, progressive nature and degree of hair loss of androgenetic alopecia are known. The therapeutic effect of oral finasteride (Propecia) was examined on androgenetic alopecia of Japanese men. The efficacy and safety of finasteride (1 mg tablet) was evaluated in Japanese men with AGA in the long term. The study enrolled 3177 men given finasteride 1 mg/day from January 2006 to June 2009 at our clinic. Efficacy was evaluated in 2561 men by the modified global photographic assessment; the photographs were assessed using the standardized 7-point rating scale. Safety data were assessed by interviews and laboratory tests in all men enrolled in the study. The overall effect of hair growth was seen in 2230 of 2561 men (87.1%), in whom hair greatly (11.1%), moderately (36.5%) and slightly (39.5%) increased. The response rate improved with increasing duration of treatment. Adverse reactions occurred in 0.7% (23/3177) of men; seven men discontinued treatment based on risk-benefit considerations. No specific safety problems associated with long-term use were observed. This study represents data collected at a single institution. Many patients did not receive follow-up examination. In Japanese men with AGA, oral finasteride used in the long-term study maintained progressive hair regrowth without recognized side-effect.
|
Quote je nu die Japanse dermatologe studie? (we weten dat je dom bent, maar een linkje kan je toch nog wel net copy paste hier he?)
Is al lang ontkracht. Meerdere problemen mee, dermatologen hebben een conflict of interest. Ze gebruikten een questionnaire om te kijken of mensen bijwerkingen ervaarde en geen medische evaluatie met bv bloed tests, etc. En de mannen die gebruikt werden waren relatief oud. Waren nog issues mee ook maar herinner me niet, als je link geeft kan ik er beter op ingaan.
Trouwens ik heb al een meta analyse studie gepost, raar dat je die negeerde he?
https://www.ncbi.nlm.nih.gov/pubmed/25830296
Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
CONCLUSIONS AND RELEVANCE:
Available toxicity information from clinical trials of finasteride in men with AGA is very limited, is of poor quality, and seems to be systematically biased. In a cohort of men prescribed finasteride for routine treatment of AGA, most would have been excluded from the pivotal studies that supported US Food and Drug Administration approval for AGA.
Published reports of clinical trials provide insufficient information to establish the safety profile for finasteride in the treatment of AGA.
Deze studie zal je vriendje Kevin Mann vergeten zijn om te vermelden zeker.
